Correction: Mid-Day Update: U.S. Stocks Decline After Weak Jobs Data; Construction Spending Also Unexpectedly Falls

Repeating 12:33 p.m. Mid-Day Update to correct for bad line breaks in original text.

U.S. stocks were lower in midday trading Wednesday following weaker-than-expected hiring and housing data today.

Private sector employers added 189,000 new workers during March, according to Automatic Data Processing ( ADP ), coming in below the 250,000 hires economists were expecting.

U.S. construction spending also fell 0.1% in February, surprising experts expecting a 0.2% increase. January construction also was revised downward to a 1.7% decline from initial reports of a 1.1% drop while December spending was raised to a 1.0% increase from original reports of a 0.8% gain.

Crude oil for May delivery was up 2.98% at $49.01 per barrel. Natural gas was down 1.3% at $2.60 per 1 million BTU. Gold was up 1.52% to $1,201 an ounce, while silver was down up 1.46% at $16.48 an ounce. Copper was up 0.29% at $2.75 per pound.

Among energy ETFs, the United States Oil Fund ( USO ) was up 3.4% $17.42 with the United States Natural Gas ( UNG ) was down 1.21% at $13.08. Among precious-metal funds, the Market Vectors Gold Miners ETF ( GDX ) was up 3.15% at $18.82 while SPDR Gold Shares.

Here's where the U.S. markets stand at mid-day:

NYSE Composite Index down 19.32 (-0.18%) to 10,879.86

Dow Jones Industrial Average down 126.68 (-0.71%) to 17,649.44

S&P 500 down 12.99 (-0.63%) to 2,054.90

Nasdaq Composite Index down 38.47 (-0.78%) to 4,862.42


Nikkei 225 Index down 0.90%

Hang Seng Index up 0.73%

Shanghai China Composite Index up 1.66%

FTSE 100 Index up 0.54%

CAC 40 up 0.57%

DAX up 0.29%


NYSE Energy Sector Index up 0.77%

NYSE Financial Sector Index up 0.09%

NYSE Healthcare Sector Index down 0.79%



(+) IMDZ, Reports positive results from Phase III testing of two immuno-oncology agents, supporting continued product development.

(+) FI, Announces plans to trim its workforce by 400 to 600 employees.

(+) DYAX, Climbs to more than a 14-year high after saying its DX-2930 drug candidate demonstrated positive pharmacokinetic, biomarker, and efficacy results during Phase Ib testing.


(-) TM, Reports 4.9% increase in March sales compared with year-ago levels to 225,959 units, topping estimates for a 4.4% gain.

(-) MSI, Acquires privately held PublicEngines, which provides cloud-based crime analysis, predictive policing and citizen engagement applications for law enforcement agencies and governments.

(-) AKAO, Falls to a lifetime low after saying it plans to start an additional Phase II trial to evaluate the safety and effectiveness of its plazomicin drug candidate for the treatment of complicated urinary tract infections.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Founded in 1999, MT Newswires (formerly known as Midnight Trader) is a leading provider of original source, multi-asset class, real-time, global financial news and information to most of the largest banks, brokerage firms and professional market data, trading & research applications in North America.

    Learn More